These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 25533764)

  • 1. Detection of breast cancer microcalcification using (99m)Tc-MDP SPECT or Osteosense 750EX FMT imaging.
    Felix DD; Gore JC; Yankeelov TE; Peterson TE; Barnes S; Whisenant J; Weis J; Shoukouhi S; Virostko J; Nickels M; McIntyre JO; Sanders M; Abramson V; Tantawy MN
    Nucl Med Biol; 2015 Mar; 42(3):269-73. PubMed ID: 25533764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Approach to Breast Cancer Diagnosis via PET Imaging of Microcalcifications Using (18)F-NaF.
    Wilson GH; Gore JC; Yankeelov TE; Barnes S; Peterson TE; True JM; Shokouhi S; McIntyre JO; Sanders M; Abramson V; Ngyuen TQ; Mahadevan-Jansen A; Tantawy MN
    J Nucl Med; 2014 Jul; 55(7):1138-43. PubMed ID: 24833491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
    Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
    Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-phase (99m)Tc-MIBI scintigraphy with delayed neck and thorax SPECT/CT and bone scintigraphy in patients with primary hyperparathyroidism: correlation with clinical or pathological variables.
    Qiu ZL; Wu B; Shen CT; Zhu RS; Luo QY
    Ann Nucl Med; 2014 Oct; 28(8):725-35. PubMed ID: 25120244
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Alves CRR; Faria DP; Carneiro CG; Garcez AT; Gutierrez VP; das Neves W; de Almeida NR; Cury Y; Chammas R; Brum PC
    Life Sci; 2018 Aug; 206():29-34. PubMed ID: 29778807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative
    Coskun N; Cagdas B; Yildirim N
    Hell J Nucl Med; 2022; 25(2):132-137. PubMed ID: 35913859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-individual comparison of
    Bénard F; Harsini S; Wilson D; Zukotynski K; Abikhzer G; Turcotte E; Cossette M; Metser U; Romsa J; Martin M; Mar C; Saad F; Soucy JP; Eigl BJ; Black P; Krauze A; Burrell S; Nichol A; Tardif JC
    Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
    Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
    J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-head comparison of
    Zhang Y; Lin Z; Li T; Wei Y; Yu M; Ye L; Cai Y; Yang S; Zhang Y; Shi Y; Chen W
    Sci Rep; 2022 Sep; 12(1):15993. PubMed ID: 36163353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 99mTc-labeled estradiol as an estrogen receptor probe: Preparation and preclinical evaluation.
    Xia X; Feng H; Li C; Qin C; Song Y; Zhang Y; Lan X
    Nucl Med Biol; 2016 Jan; 43(1):89-96. PubMed ID: 26466867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accurate characterization of
    Zhang L; He Q; Zhou T; Zhang B; Li W; Peng H; Zhong X; Ma L; Zhang R
    BMC Med Imaging; 2019 May; 19(1):44. PubMed ID: 31146746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A report on the incidence of intestinal 99mTc-methylene diphosphonate uptake of bone scans and a review of the literature.
    Ergün EL; Kiratli PO; Günay EC; Erbaş B
    Nucl Med Commun; 2006 Nov; 27(11):877-85. PubMed ID: 17021428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
    Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
    Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma.
    Chakraborty D; Bhattacharya A; Mete UK; Mittal BR
    Clin Nucl Med; 2013 Aug; 38(8):616-21. PubMed ID: 23603596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of Na[
    Usmani S; Ahmed N; Gnanasegaran G; Al Kandari F; Marafi F; Bani-Mustafa A; Musbah A; Jassem Almashmoum M; Van den Wyngaert T
    Acta Oncol; 2022 Oct; 61(10):1230-1239. PubMed ID: 35862646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions.
    Ergün EL; Kara PO; Gedik GK; Kars A; Türker A; Caner B
    Ann Nucl Med; 2007 Jul; 21(5):275-83. PubMed ID: 17634845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of (99m)Tc-MDP SPECT for assessment of mandibular growth: development of normal values.
    Fahey FH; Abramson ZR; Padwa BL; Zimmerman RE; Zurakowski D; Nissenbaum M; Kaban LB; Treves ST
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):1002-10. PubMed ID: 20033153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
    Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
    J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
    Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.